To hear about similar clinical trials, please enter your email below
Trial Title:
Treatments for Brain Metastases With Poor Prognostic Factors
NCT ID:
NCT05609162
Condition:
Brain Metastases
Conditions: Official terms:
Neoplasm Metastasis
Brain Neoplasms
Conditions: Keywords:
Brain Metastases
local treatments
systemic treatments
poor prognosis
Study type:
Observational
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Procedure
Intervention name:
neurosurgical resection
Description:
neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT),
EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
Arm group label:
local treatment group vs local treatment+systemic treatment group
Arm group label:
local treatment group vs non-local treatment group
Arm group label:
local treatment group vs systemic treatment group
Arm group label:
local treatment+systemic treatment group vs non-local treatment+systemic treatment group
Arm group label:
systemic treatment group vs local treatment+systemic treatment group
Other name:
radiation
Other name:
chemotherapy
Other name:
target therapy
Summary:
The goal of this observational study is to learn about treatments in brain metastases
with poor prognostic factors. The main questions it aims to answer are:
- What kind of local treatment provides a survival benefit for patients with poor
prognostic factors?
- What kind of systemic treatment provides a survival benefit for patients with poor
prognostic factors?
- Will the combination of local treatment and systemic treatment provide a survival
benefit for patients with poor prognostic factors?
Participants will be asked to provide personal information about their living status,
symptoms, and disease control during the follow-up.
Criteria for eligibility:
Study pop:
Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University
Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First
Affiliated Hospital of Guangxi Medical University will be selected.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Evidence of pathological diagnosis of primary tumor;
2. Brain metastases confirmed by enhanced magnetic resonance imaging;
3. Complete clinical information
Exclusion Criteria:
1. Survival time less than 30 days;
2. If surgical treatment is accepted, the surgical treatment is not tumor resection,
but ventricle puncture, biopsy and other non-tumor reducing surgery;
3. Incomplete clinical data;
4. Patients with 2 or more types of tumors.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Sun Yat-sen University Cancer Center
Address:
City:
Guangzhou
Zip:
510006
Country:
China
Start date:
December 15, 2022
Completion date:
November 20, 2024
Lead sponsor:
Agency:
Sun Yat-sen University
Agency class:
Other
Collaborator:
Agency:
Cancer Hospital of Guangxi Medical University
Agency class:
Other
Collaborator:
Agency:
Guangxi Zhuang Autonomous Region People's Hospital
Agency class:
Other
Collaborator:
Agency:
First Affiliated Hospital of Guangxi Medical University
Agency class:
Other
Source:
Sun Yat-sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05609162
